Follow Naijacrux on twitter .follow us on Twitter www.twitter.com/naijacruxonline, or @naijacruxonline or search for naijacruxonline on twitter!!Like us on facebook .Like us at www.facebook.com/Naijacruxforum.Click Here To Last longer In Bed[Stay amused>>>Don’t be a one minute Foul]>>> Love need Tips-See how Here


Author Topic: US Approves Bladder Cancer Drug  (Read 13195 times)

0 Members and 1 Guest are viewing this topic.

Offline Postmaster

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 1104
  • Karma: +0/-0
US Approves Bladder Cancer Drug
« on: April 15, 2019, 07:22:40 AM »
Loading...


Johnson & Johnson's drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration
announced Friday.

The list price of the drug, known chemically as erdafitinib, will range between $10,080 and $22,680 for a 28-day supply, depending on the dosage, J&J said.

Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division.

The drug is approved for use in patients whose cancer has progressed during or after chemotherapy and have specific genetic alterations known as FGFR3 or FGFR2. Patients will be selected for therapy with Balversa using an FDA-approved companion diagnostic device that will identify the genetic
mutations, the agency said.

Bladder cancer is the sixth most common cancer in the United States, with the FGFR alterations present in about one in five patients.

"We're in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient's specific genetic mutation or biomarker is becoming the standard," Richard Pazdur, head of the FDA's oncology products division, said in a statement.

J&J shares closed up 0.5 percent at $135.98. Shares of Incyte Corp., which is also developing a FGFR inhibitor, closed down 2 percent at $79.40.

The approval was based on a small 87-patient trial in which about a third of subjects experienced tumor shrinkage. The median duration before disease progression was 5.4 months.

Common side effects of the drug include high phosphate levels, mouth sores and fatigue. The drug may cause serious eye problems, including inflamed eyes, the FDA said.


 

 

Drug Maker Johnson & Johnson to Split Into Two Companies

Started by gurusforum

Replies: 0
Views: 14818
Last post November 17, 2021, 12:34:07 PM
by gurusforum
Ebola drug "ZMapp" trial begins in Liberia

Started by admin

Replies: 0
Views: 1946
Last post February 27, 2015, 11:19:22 PM
by admin
United Nations Warns of Low risk Distribution of AIDS Drug Amid COVID Lockdowns

Started by lindaikeji

Replies: 0
Views: 16637
Last post June 24, 2020, 08:34:38 AM
by lindaikeji
World health organization urge Drug Companies to Share Vaccine-Making Facilities

Started by Postmaster

Replies: 0
Views: 12504
Last post February 08, 2021, 11:17:36 AM
by Postmaster
Nigerians blast US FDA for calling its Ebola trial drug 'Nano Silver a pesticide

Started by internet police

Replies: 0
Views: 1608
Last post August 17, 2014, 02:40:59 PM
by internet police